Related Experiment Video

Updated: Sep 23, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer

José Hernández-Rodríguez1, Ana García-Martínez, Jordi Casademont

  • 1University of Barcelona, Institute d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

Arthritis and Rheumatism
|April 5, 2002
PubMed

Insights

Patients with giant cell arteritis (GCA) and a strong initial inflammatory response require longer corticosteroid treatment and experience more flares. A strong inflammatory response in GCA predicts a more challenging treatment course.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Giant cell arteritis (GCA) is a systemic vasculitis affecting large arteries.
  • The initial inflammatory response intensity in GCA may influence treatment outcomes.
  • Predicting treatment response is crucial for managing GCA effectively.

Purpose of the Study:

  • To determine if the intensity of the initial systemic inflammatory response predicts therapeutic response in giant cell arteritis (GCA) patients.
  • To investigate the relationship between baseline inflammatory markers and treatment duration, disease flares, and corticosteroid requirements.

Main Methods:

  • Retrospective review of 75 biopsy-proven GCA patients.
  • Assessment of baseline inflammatory response using four parameters: fever, weight loss, elevated ESR, and low hemoglobin.
  • Categorization into weak (≤2 parameters) and strong (3-4 parameters) inflammatory response groups.
  • Analysis of time to prednisone maintenance dose, disease flares, and cumulative steroid doses using Kaplan-Meier survival analysis.
  • Measurement of serum interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) levels.

Main Results:

  • Patients with a strong initial inflammatory response (group 2) showed significantly higher circulating levels of TNFalpha and IL-6 compared to those with a weak response (group 1).
  • Group 2 patients required a significantly longer median time (62 weeks) to reach a low prednisone maintenance dose (<10 mg/day) compared to group 1 (40 weeks).
  • Patients with a strong inflammatory response experienced more disease flares and received higher cumulative corticosteroid doses during therapy.

Conclusions:

  • A strong initial systemic inflammatory reaction in GCA is associated with elevated IL-6 and TNFalpha levels.
  • GCA patients with a strong inflammatory response exhibit higher and more prolonged corticosteroid requirements.
  • A strong inflammatory response predicts an increased frequency of disease flares during corticosteroid therapy for GCA.
Abstract

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Related Concept Videos

Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...